A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?
This article was originally published in The Pink Sheet Daily
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.
You may also be interested in...
Lilly's comprehensive R&D initiative to lead in Alzheimer’s disease includes seven drugs in or nearing the clinic, with an eye on combinations. But until data from a third Phase III trial testing solanezumab read out in late 2016/early 2017, investors remain skeptical.
The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.